The Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Feb. 27 provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Fourth quarter Net loss allocable to common stockholders was $23.5 million, or $0.11 per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $7.13 in last session, and closed at $6.68, while the day range of ARNA stock is $6.64-$7.18.The stock showed a negative weekly performance of -5.65%.
Arrowhead Research Corp (NASDAQ:ARWR) shares are soaring; a rally that started in pre-market trading has been sustained in the regular session. Already the shares have set a new high for the year which is also the new 12 months high for the stock. As usual, there must be something behind the excitement around ARWR and this is what we are exploring in this article. Arrowhead Research Corp (NASDAQ:ARWR) stock opened at $23.06, in last session and closed at $23.06, by loosed -8.35%.The 52 week range was $1.65-$27.63.Company’s market capitalization is $1.05 billion.
The Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) on Feb. 25 announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014. Adjusted net income for 2013 was $388.3 million, or $6.31 per diluted share, compared to $290.4 million, or $4.82 per diluted share, for 2012. Adjusted net income for the fourth quarter of 2013 was $106.1 million, or $1.72 per diluted share, compared to $93.9 million, or $1.53 per diluted share, for the fourth quarter of 2012. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) stock loosed -5.19% and finished the last session at $149.30.The EPS of the stock remained 3.51.Company’s market capitalization is $9.15 billion.
Illumina, Inc. (NASDAQ:ILMN) provides a wide range of genetic analysis products. It is mostly in the development and manufacturing of life science tools as well as integrated systems that are used in the analysis of genetic function and variation. Thus, its range of services and products has wide application in genotyping, sequencing, molecular diagnostics and gene expression. Illumina, Inc. (NASDAQ:ILMN) stock opened the session at $168.78, and closed the session at $159.20. The 52 week range of the ILMN stock remained $50.30-$183.30 and the day range was $157.99-$169.12.